Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Abstract RF3-05: Tissue-free circulating tumour DNA detection in patients with early triple negative breast cancer from the c-TRAK-TN trial

ctDNA was detected by Reveal in 54/159 (34.0%) patients at least once and was associated with relapse (HR 20.62, P<0.0001). Of patients who relapsed by 24 months, 34/38 (89.5%) had prior ctDNA detection. Agreement with ddPCR was 94.5% (950/1005 timepoints). Among detections, 44.8% were first found by the tissue-free assay and 6.9% by ddPCR. Median time from first detection to relapse was 7.9 months with Reveal vs 5.7 months with ddPCR (HR 0.6, P=0.0574).

San Antonio Breast Cancer Symposium 2025PubMed 36423745